Additionally, combining HSP90-targeting photodynamic therapy (HS201-PDT) with an anti-PD-L1 antibody significantly increased tumor suppression and survival rates compared to monotherapy (p < 0.01), increased the activation of CD8+ T cells, and exhibited an abscopal effect in distant tumors through immune activation mediated by the CXCR3-related pathway [124]. The gene discussed is HSP90AB1; the disease is neoplasm.